Manufacturing system for diverse hormone preparations and high-volume supply
First written in FY2020. 4 of 5 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「To meet growing demand for these core products, the new tablet building constructed at the Toyama Plant to manufacture hormone tablets is scheduled to begin full-scale operations in 2023. We will expand hormone-tablet production capacity, contribute further to improving women's well-being and fulfil our responsibility to ensure a stable supply.」
It continues to pursue the policy of developing a supply system aimed at expanding production capacity for hormone tablets and ensuring a stable supply. - FY2023-Q2RestatedAnnual report
「The company will expand production capacity for hormone tablets, contribute further to improving women's well-being, and fulfill its responsibility to ensure a stable supply.」
It continues to pursue initiatives to expand production capacity and ensure a stable supply, consistent with the policy of establishing a diversified, high-volume supply system including hormone preparations. - FY2022RestatedAnnual report
「The company will establish a system for supplying a wide range of products in high volumes and will manufacture and sell products including not only female hormones but also male hormones and anticancer drugs.」
It continues to pursue the policy of establishing a diversified, high-volume supply system covering female hormones, male hormones, anticancer drugs and other products. - FY2021RestatedAnnual report
「The company will establish a system for supplying a wide range of products in high volumes and will manufacture and sell products including not only female hormones but also male hormones and anticancer drugs.」
It continues to pursue the policy of establishing a diversified, high-volume supply system covering female hormones, male hormones and anticancer drugs. - FY2020First statedAnnual report
「The company will establish a system for supplying a wide range of products in high volumes and will manufacture and sell products including not only female hormones but also male hormones and anticancer drugs.」
It describes an initiative to establish a diversified, high-volume supply system for a broad range of products, including male hormones and anticancer drugs in addition to female hormones.